Bio-Rad Laboratories, Inc. (NYSE:BIO) Receives $358.20 Consensus Price Target from Analysts
Shares of Bio-Rad Laboratories, Inc. (NYSE:BIO – Get Free Report) have been assigned a consensus recommendation of “Hold” from the five analysts that are currently covering the company, MarketBeat.com reports. Three research analysts have rated the stock with a hold recommendation and two have issued a buy recommendation on the company. The average 1 year […]
More Stories
AGNC Investment Corp. (NASDAQ:AGNCO) Plans $0.41 Quarterly Dividend
AGNC Investment Corp. (NASDAQ:AGNCO – Get Free Report) announced a quarterly dividend on Friday, September 13th, NASDAQ reports. Shareholders of...
Agilent Technologies, Inc. (NYSE:A) Announces $0.24 Quarterly Dividend
Agilent Technologies, Inc. (NYSE:A – Get Free Report) declared a quarterly dividend on Wednesday, September 18th, NASDAQ reports. Investors of...
Lebanon crisis: over one million people flee strikes amid invasion fears
More than one million people across Lebanon have been uprooted by ongoing and deadly Israeli airstrikes across the country, including...
Chord Energy Co. (NASDAQ:CHRD) Given Average Recommendation of “Moderate Buy” by Analysts
Chord Energy Co. (NASDAQ:CHRD – Get Free Report) has received a consensus recommendation of “Moderate Buy” from the eleven research...
Royce Micro-Cap Trust, Inc. (NYSE:RMT) Short Interest Update
Royce Micro-Cap Trust, Inc. (NYSE:RMT – Get Free Report) was the recipient of a significant decrease in short interest in...
One Liberty Properties, Inc. (NYSE:OLP) Short Interest Update
One Liberty Properties, Inc. (NYSE:OLP – Get Free Report) was the recipient of a large drop in short interest during...